DE

477.85

+1.78%↑

FDX

241.56

-0.91%↓

CPRT

57.2

+1.13%↑

HEICO

269.51

+0.96%↑

HEICA

212.51

+0.9%↑

DE

477.85

+1.78%↑

FDX

241.56

-0.91%↓

CPRT

57.2

+1.13%↑

HEICO

269.51

+0.96%↑

HEICA

212.51

+0.9%↑

DE

477.85

+1.78%↑

FDX

241.56

-0.91%↓

CPRT

57.2

+1.13%↑

HEICO

269.51

+0.96%↑

HEICA

212.51

+0.9%↑

DE

477.85

+1.78%↑

FDX

241.56

-0.91%↓

CPRT

57.2

+1.13%↑

HEICO

269.51

+0.96%↑

HEICA

212.51

+0.9%↑

DE

477.85

+1.78%↑

FDX

241.56

-0.91%↓

CPRT

57.2

+1.13%↑

HEICO

269.51

+0.96%↑

HEICA

212.51

+0.9%↑

Search

India Globalization Capital Inc

Suletud

0.28

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.28

Max

0.29

Põhinäitajad

By Trading Economics

Sissetulek

-112K

-1.8M

Müük

-155K

257K

Kasumimarginaal

-711.673

Töötajad

67

EBITDA

-263K

-1.9M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+1417.86% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

20. juuni 2025

Turustatistika

By TradingEconomics

Turukapital

23M

Eelmine avamishind

0.28

Eelmine sulgemishind

0.28

India Globalization Capital Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. sept 2024, 04:00 UTC

Peamised uudised

Novo, Amgen, Other Pharma Stocks Have Clinical Trials That Could Send Them Soaring -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

India Globalization Capital Inc Prognoos

Hinnasiht

By TipRanks

1417.86% tõus

12 kuu keskmine prognoos

Keskmine 4.25 USD  1417.86%

Kõrge 4.25 USD

Madal 4.25 USD

Põhineb 1 Wall Streeti analüütiku instrumendi India Globalization Capital Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

1

Osta

0

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest India Globalization Capital Inc

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.